- The global lung cancer therapeutics market, offering pharmaceutical and biological interventions for the treatment of lung cancer, is increasingly vital for addressing the growing global health burden of this disease in both early and advanced stages due to their enhanced efficacy, improved patient outcomes, and potential for integration with personalized medicine approaches
- The escalating demand for lung cancer therapeutics is primarily fueled by the widespread increase in lung cancer incidence linked to factors such as smoking and pollution, growing concerns among healthcare providers and patients regarding effective treatment options, and a rising preference for the convenience and precision of modern therapies such as targeted and immunotherapies
- North America dominates the lung cancer therapeutics market with the largest revenue share of 31.5% in 2025, characterized by early adoption of advanced treatment modalities, high healthcare expenditure, and a strong presence of key pharmaceutical and biotechnology companies
- Asia-Pacific is expected to be the fastest growing region in the lung cancer therapeutics market with CAGR of 12.8% during the forecast period due to increasing urbanization and rising disposable incomes leading to improved healthcare access and a growing patient population
- Targeted therapy segment is expected to dominate the lung cancer therapeutics market with a market share of 50.5% in 2025, driven by its effectiveness in treating specific genetic mutations prevalent in lung cancer, leading to improved patient outcomes and reduced off-target toxicities compared to traditional chemotherapy
